BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu TC, Vachharajani N, Chapman WC, Brunt EM. SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event: a study of 236 cases. Am J Surg Pathol 2014;38:966-72. [PMID: 24805857 DOI: 10.1097/PAS.0000000000000218] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Park H, Lee H, Seo AN, Cho JY, Choi YR, Yoon YS, Han HS, Park YN, Kim H. SALL4 Expression in Hepatocellular Carcinomas Is Associated with EpCAM-Positivity and a Poor Prognosis. J Pathol Transl Med 2015;49:373-81. [PMID: 26265684 DOI: 10.4132/jptm.2015.07.09] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
2 Singhi AD, Seethala RR, Nason K, Foxwell TJ, Roche RL, McGrath KM, Levy RM, Luketich JD, Davison JM. Undifferentiated carcinoma of the esophagus: a clinicopathological study of 16 cases. Hum Pathol 2015;46:366-75. [PMID: 25582499 DOI: 10.1016/j.humpath.2014.11.021] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
3 Shibahara J, Ando S, Hayashi A, Sakamoto Y, Hesegawa K, Kokudo N, Fukayama M. Clinicopathologic characteristics of SALL4-immunopositive hepatocellular carcinoma. Springerplus 2014;3:721. [PMID: 26034695 DOI: 10.1186/2193-1801-3-721] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
4 Jung YK, Jang K, Paik SS, Kwon YJ, Kim HJ, Lee KG, Park HK, Choi D. Positive immunostaining of Sal-like protein 4 is associated with poor patient survival outcome in the large and undifferentiated Korean hepatocellular carcinoma. Ann Surg Treat Res 2016;91:23-8. [PMID: 27433461 DOI: 10.4174/astr.2016.91.1.23] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
5 Deng G, Zhu L, Huang F, Nie W, Huang W, Xu H, Zheng S, Yi Z, Wan T. SALL4 is a novel therapeutic target in intrahepatic cholangiocarcinoma. Oncotarget. 2015;6:27416-27426. [PMID: 26317546 DOI: 10.18632/oncotarget.4862] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
6 Yang Y, Wang X, Liu Y, Hu Y, Li Z, Li Z, Bu Z, Wu X, Zhang L, Ji J. Up-Regulation of SALL4 Is Associated With Survival and Progression via Putative WNT Pathway in Gastric Cancer. Front Cell Dev Biol 2021;9:600344. [PMID: 33644042 DOI: 10.3389/fcell.2021.600344] [Reference Citation Analysis]
7 Cheng J, Gao J, Shuai X, Tao K. Oncogenic protein SALL4 and ZNF217 as prognostic indicators in solid cancers: a meta‑analysis of individual studies. Oncotarget 2016;7:24314-25. [PMID: 27007163 DOI: 10.18632/oncotarget.8237] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
8 Cruz W, Huang H, Barber B, Pasini E, Ding L, Zheng G, Chen J, Bhat M. Lipoprotein-Like Nanoparticle Carrying Small Interfering RNA Against Spalt-Like Transcription Factor 4 Effectively Targets Hepatocellular Carcinoma Cells and Decreases Tumor Burden. Hepatol Commun 2020;4:769-82. [PMID: 32363325 DOI: 10.1002/hep4.1493] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Qu L, Zhu H, Wang M. Micro-Inversions In Human Cancer Genomes. Annu Int Conf IEEE Eng Med Biol Soc 2018;2018:1323-6. [PMID: 30440635 DOI: 10.1109/EMBC.2018.8512514] [Reference Citation Analysis]
10 Nicolè L, Sanavia T, Veronese N, Cappellesso R, Luchini C, Dabrilli P, Fassina A. Oncofetal gene SALL4 and prognosis in cancer: A systematic review with meta-analysis. Oncotarget 2017;8:22968-79. [PMID: 28160555 DOI: 10.18632/oncotarget.14952] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
11 Chen L, Ni CF, Chen SX, Cao JM, Zhu HD, Guo JH, Zhu GY, Zhong BY, Ding W, He SC, Deng G, Teng GJ. A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients. J Vasc Interv Radiol 2016;27:1288-97. [PMID: 27013402 DOI: 10.1016/j.jvir.2015.12.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
12 Huang LH, Hsieh TM, Huang CY, Liu YW, Wu SC, Chien PC, Hsieh CH. Disparity of Hepatocellular Carcinoma in Tumor Microenvironment-Related Genes and Infiltrating Immune Cells between Asian and Non-Asian Populations. Genes (Basel) 2021;12:1274. [PMID: 34440448 DOI: 10.3390/genes12081274] [Reference Citation Analysis]
13 Zhou S, Venkatramani R, Gupta S, Wang K, Stein JE, Wang L, Mascarenhas L. Hepatocellular malignant neoplasm, NOS: a clinicopathological study of 11 cases from a single institution. Histopathology 2017;71:813-22. [PMID: 28660626 DOI: 10.1111/his.13297] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]